TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29417771

Group type: EXPERIMENTAL
Intervention: Traditional nail plate system (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Zero-profile device (group B)
Number of subjects: 45
Study: 26350209

Group type: EXPERIMENTAL
Intervention: Nurse counseling (pediatrician visit every 3 months + nurse visit and phone calls)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (pediatrician visit every 3 months)
Number of subjects: 77
Study: 25326008

Group type: EXPERIMENTAL
Intervention: Dopamine 7 µg/kg/min (Group D)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Methoxamine 1 µg/kg/min (Group M1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Methoxamine 2 µg/kg/min (Group M2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Methoxamine 3 µg/kg/min (Group M3)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group receiving saline (Group C)
Number of subjects: 150
Study: 22753544

Group type: EXPERIMENTAL
Intervention: Intermittent blue light (three 30 min pulses over 2 h) once a day for 3 days of free-running
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dim room light (control)
Number of subjects: 0
Study: 19458624

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 654

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 654
Study: 17102802

Group type: EXPERIMENTAL
Intervention: Bicalutamide (Casodex) 150 mg plus standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 15831604

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary preventive treatments
Number of subjects: 0
Study: 14601488

Group type: EXPERIMENTAL
Intervention: Plasma LEP levels in AN patients
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Plasma neuropeptide Y (NPY), beta‐endorphin (B‐EP), and galanin (GAL) levels in AN
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Serum/plasma levels of insulin (I), insulin‐like growth hormone‐1 (IGF‐1), luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2), and free triiodothyronine (fT3) in AN
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cortisol (F) levels in AN
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Correlation of LEP levels with IRI, IGF‐1, free thyroxine (fT4), and FSH levels in AN
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Personality traits in patients with AN
Number of subjects: 55
Study: 10457578

Group type: EXPERIMENTAL
Intervention: Interferential therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Motorized lumbar traction and massage
Number of subjects: 152
Study: 7576673

Group type: EXPERIMENTAL
Intervention: Forced-air warming for one hour before induction of anesthesia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Wool blanket during a similar preinduction period
Number of subjects: 16
Study: 1971630

Group type: EXPERIMENTAL
Intervention: Chlorhexidine antisepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soap
Number of subjects: 0
Study: 6784917

Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ThioTEPA and methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) and Adriamycin (ADM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) or DDP-ADM
Number of subjects: 0
Study: 31488372

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents
Number of subjects: 1300
Study: 27939204

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (8 μg/kg 8 hourly)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 42
Study: 26559501

Group type: EXPERIMENTAL
Intervention: Testosterone concentrations (total and bioavailable) measured at follow-up years 10 and 17.
Number of subjects: 0
Study: 23602210

Group type: EXPERIMENTAL
Intervention: Communication skills intervention (booklet mailed prior to the consultation)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 17264863

Group type: EXPERIMENTAL
Intervention: Multidisciplinary management of bone complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 0
Study: 15508051

Group type: EXPERIMENTAL
Intervention: Mother-infant interactions with multiples
Number of subjects: 77

Group type: COMPARATOR
Intervention: Mother-infant interactions with singletons
Number of subjects: 77
Study: 10714911

Group type: EXPERIMENTAL
Intervention: 4 mg of estradiol valerate plus 200 mg of enanthate of dihydroandrosterone im monthly (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 50 microg/day of transdermal 17-b-estradiol continuously (Group E)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2.5 mg of tibolone every day (Group T)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment-free control group (Group C)
Number of subjects: 120
Study: 9468004

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24
Study: 8176626

Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg daily)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 151
Study: 3513533

Group type: EXPERIMENTAL
Intervention: Individual snacks (milk chocolate bar, granola bar, chocolate milk, peanut butter cups, yogurt, potato chips)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isocaloric snack meals (cereal-milk, cheese sandwich-milk, peanut butter sandwich-chocolate milk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual snacks
Number of subjects: 0
Study: 30024220

Group type: EXPERIMENTAL
Intervention: Exposure (EX) condition
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonexposure condition
Number of subjects: 70
Study: 28185784

Group type: EXPERIMENTAL
Intervention: Integrated Neurocognitive Therapy (INT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 61
Study: 24972015

Group type: EXPERIMENTAL
Intervention: Mortality reminders
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self-esteem threats
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Point-of-care testing device
Number of subjects: 112
Study: 23932548

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 2591

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2591
Study: 21307816

Group type: COMPARATOR
Intervention: baclofen (10 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: meclizine (50 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: cinnarizine (20 mg) + dimenhydrinate (40 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: promethazine (25 mg) + dextro‐amphetamine (5 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 20368225

Group type: EXPERIMENTAL
Intervention: Home-based exercise training program (rowing ergometry at 65-70% of peak oxygen uptake) for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 25
Study: 16950962

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (72 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mixed amphetamine salts extended release (30 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15597521

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 1000 mg qd
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 1500 mg qd
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) monotherapy
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Combination of ddI plus HU
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 134
Study: 11374699

Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) 25-30 mg/kg per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9018022

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remoxipride (150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulpiride (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8329266

Group type: EXPERIMENTAL
Intervention: Tracheal tube cuff inflated
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tracheal tube cuff deflated
Number of subjects: 20
Study: 3525023

Group type: EXPERIMENTAL
Intervention: PY 108-068 (150 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PY 108-068 (75 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30077754

Group type: EXPERIMENTAL
Intervention: Grayscale inversion view
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard view
Number of subjects: 162
Study: 27138643

Group type: EXPERIMENTAL
Intervention: tDCS-Matching
Number of subjects: 22

Group type: COMPARATOR
Intervention: tDCS-Resting
Number of subjects: 22
Study: 24871787

Group type: EXPERIMENTAL
Intervention: DA-9601 (60 mg, thrice daily)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Misoprostol (200 μg, thrice daily)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: DA-9601
Number of subjects: 520

Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 520
Study: 22730052

Group type: EXPERIMENTAL
Intervention: Ice slurry (−1.4°C; ICE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ambient temperature drink (30.9°C; CON)
Number of subjects: 12
Study: 20537558

Group type: EXPERIMENTAL
Intervention: Scopolamine patch (1.5 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 18237269

Group type: EXPERIMENTAL
Intervention: 90-microg dose of H5N1 influenza vaccine
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: 45-microg dose of H5N1 influenza vaccine
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: 15-microg dose of H5N1 influenza vaccine
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: 7.5-microg dose of H5N1 influenza vaccine
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine (third dose)
Number of subjects: 337
Study: 15457206

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazepril HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benazepril HCl/hydrochlorothiazide
Number of subjects: 0
Study: 12830564

Group type: EXPERIMENTAL
Intervention: Self-help intervention based on cognitive behaviour principles in general practice.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Specialist outpatient treatment in specialist eating disorder clinics.
Number of subjects: 68
Study: 10397217

Group type: COMPARATOR
Intervention: Standard Arrow catheter
Number of subjects: 120

Group type: COMPARATOR
Intervention: ARROWgard catheter
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bio-Guard catheter
Number of subjects: 120
Study: 8723805

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 0
Study: 1512689

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment
Number of subjects: 0
Study: 6542866

Group type: EXPERIMENTAL
Intervention: Forskolin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31283835

Group type: EXPERIMENTAL
Intervention: Pre-operative CRP ≥5 mg/dL
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Pre-operative CRP
Number of subjects: 314
Study: 28132701

Group type: EXPERIMENTAL
Intervention: SBIRT intervention (screening, brief intervention, and referral to treatment)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Control group (no SBIRT intervention)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: SBIRT intervention
Number of subjects: 732

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 732
Study: 27266498

Group type: EXPERIMENTAL
Intervention: Real-time tissue elastography
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 3D contrast-enhanced ultrasonography (CEUS)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Two joint inspection
Number of subjects: 126
Study: 24879388

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) with 25g glucose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isoglycaemic intravenous glucose infusion (IIGI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) with 75g and 125g glucose
Number of subjects: 16
Study: 22002325

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA
Number of subjects: 0
Study: 19101598

Group type: EXPERIMENTAL
Intervention: Mindfulness-based weight loss intervention (four 2-hour workshops)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (normal diet)
Number of subjects: 62
Study: 17240248

Group type: EXPERIMENTAL
Intervention: Residents-as-teachers program (10.5-hour workshop)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 15230100

Group type: EXPERIMENTAL
Intervention: Ubiquitous biotherapy in 40 patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group treated according to generally accepted principles (30 patients)
Number of subjects: 70
Study: 11772900

Group type: EXPERIMENTAL
Intervention: Diabetes medication or weight-reduction program for patients with IGT
Number of subjects: 3638

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3638
Study: 9682550

Group type: EXPERIMENTAL
Intervention: Subgingival scaling using ultrasonic scalers and local anaesthesia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subgingival scaling using ultrasonic scalers and local anaesthesia plus systemic metronidazole (200 mg tds for 7 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subgingival scaling using ultrasonic scalers and local anaesthesia plus two applications of 25% metronidazole gel one week apart
Number of subjects: 90
Study: 9234259

Group type: EXPERIMENTAL
Intervention: 125I‐B72.3 (1 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 125I‐B72.3 (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 131I‐CC49 (1 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 131I‐CC49 (20 mg)
Number of subjects: 10
Study: 2920999

Group type: EXPERIMENTAL
Intervention: Propranolol (15 mg intravenous single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg per day chronic oral administration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (15 mg intravenous single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (160 mg per day chronic oral administration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol and Placebo
Number of subjects: 16
Study: 31689007

Group type: COMPARATOR
Intervention: WL (Weight Loss)
Number of subjects: 222

Group type: COMPARATOR
Intervention: WL + AT (Weight Loss plus Aerobic Training)
Number of subjects: 222

Group type: COMPARATOR
Intervention: WL + RT (Weight Loss plus Resistance Training)
Number of subjects: 222
Study: 28062685

Group type: EXPERIMENTAL
Intervention: Predictive scoring model for all-cause 30 day mortality based on logistic regression including factors such as age >50 years, infection due to Klebsiella spp., source other than urinary tract, fatal underlying disease, Pitt score >3, severe sepsis or septic shock at presentation, and inappropriate early targeted therapy.
Number of subjects: 950
Study: 26193907

Group type: EXPERIMENTAL
Intervention: Partnership-based self-management programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study: 23914988

Group type: EXPERIMENTAL
Intervention: Metyrapone 500 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21565593

Group type: EXPERIMENTAL
Intervention: Psychophysiological treatment (PT), 10 sessions, manualized, individually-administered
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Psychophysiological treatment (PT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard medical care augmented by psychiatric consultation (wait-list)
Number of subjects: 38
Study: 19593170

Group type: EXPERIMENTAL
Intervention: Algorithm-guided standardized stepwise drug treatment regimen (SSTR)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 148
Study: 17227922

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 104

Group type: COMPARATOR
Intervention: Proton pump inhibitors (optimized medical therapy)
Number of subjects: 104
Study: 12478127

Group type: EXPERIMENTAL
Intervention: Orchiectomy and flutamide
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Orchiectomy and placebo
Number of subjects: 1076
Study: 10898413

Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (non-irradiated patients in BERT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (non-irradiated patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 8817407

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, sublingual)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 28
Study: 1422288

Group type: EXPERIMENTAL
Intervention: 2% lidocaine containing 1:80,000 epinephrine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2% lidocaine containing 1:25,000 norepinephrine
Number of subjects: 19
Study: 4059722

Group type: EXPERIMENTAL
Intervention: Dinamap 845
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dinamap (during emotional pressor response assessment)
Number of subjects: 0
Study: 2897305

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride
Number of subjects: 40
Study: 31823111

Group type: EXPERIMENTAL
Intervention: SUP mobile app
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment condition (control)
Number of subjects: 0
Study: 29533751

Group type: EXPERIMENTAL
Intervention: Tonsillectomy (TE) in childhood
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (matched individuals)
Number of subjects: 132
Study: 28992467

Group type: EXPERIMENTAL
Intervention: 10 mg daily rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline ADMA (highest tertile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin randomization
Number of subjects: 0
Study: 26120980

Group type: EXPERIMENTAL
Intervention: Baclosan in combination with standard therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 103
Study: 23020859

Group type: EXPERIMENTAL
Intervention: Minimized perfusion circuit (MPC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional circulatory perfusion bypass (CCPB)
Number of subjects: 28
Study: 21940214

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rituximab
Number of subjects: 823

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rituximab (favourable subgroup, IPI=0, no bulk)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Chemotherapy alone (less favourable subgroup, IPI=1 or bulk, or both)
Number of subjects: 823
Study: 19069803

Group type: EXPERIMENTAL
Intervention: Magneto-laser therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low-intensity laser therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 75
Study: 16997055

Group type: EXPERIMENTAL
Intervention: Collaborative team model (INT)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual physician-managed care (UC)
Number of subjects: 223
Study: 13130087

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials published in podiatric medical journals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials published in a mainstream medical journal
Number of subjects: 0
Study: 11008052

Group type: EXPERIMENTAL
Intervention: Acular (ketorolac tromethamine 0.5%)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ocufen (flurbiprofen sodium) preoperatively and Pred Forte (prednisolone acetate 1%) postoperatively
Number of subjects: 26
Study: 8630720

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1000 micrograms bid for 16 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1000 micrograms bid for 1 year (open-label)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate after switching from placebo during open-label period
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: FEV1 measurement at the end of the double-blind period
Number of subjects: 96
Study: 1294818

Group type: EXPERIMENTAL
Intervention: Combined treatment administered during RA remission
Number of subjects: 94
Study: 6199450

Group type: EXPERIMENTAL
Intervention: Cibenzoline (maximum dose)
Number of subjects: 5
Study: 30615671

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Former and never smokers
Number of subjects: 0
Study: 29661916

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG)
Number of subjects: 96